417,900 Shares in MiMedx Group, Inc. (NASDAQ:MDXG) Purchased by Norges Bank

Norges Bank purchased a new stake in MiMedx Group, Inc. (NASDAQ:MDXG) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 417,900 shares of the company’s stock, valued at approximately $4,020,000. Norges Bank owned approximately 0.28% of MiMedx Group at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of MDXG. The Manufacturers Life Insurance Company grew its holdings in shares of MiMedx Group by 35.3% during the third quarter. The Manufacturers Life Insurance Company now owns 61,706 shares of the company’s stock worth $365,000 after buying an additional 16,083 shares in the last quarter. FMR LLC boosted its position in MiMedx Group by 29.8% during the third quarter. FMR LLC now owns 53,869 shares of the company’s stock worth $318,000 after acquiring an additional 12,371 shares during the last quarter. Verition Fund Management LLC purchased a new stake in MiMedx Group during the 3rd quarter valued at about $131,000. Wellington Management Group LLP raised its holdings in MiMedx Group by 11.8% in the 3rd quarter. Wellington Management Group LLP now owns 317,274 shares of the company’s stock valued at $1,875,000 after acquiring an additional 33,461 shares during the last quarter. Finally, Jane Street Group LLC lifted its stake in MiMedx Group by 133.6% in the 3rd quarter. Jane Street Group LLC now owns 305,652 shares of the company’s stock worth $1,806,000 after purchasing an additional 174,797 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price target on shares of MiMedx Group in a research report on Thursday, February 27th. StockNews.com raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 4th.

Insider Activity at MiMedx Group

In other MiMedx Group news, CAO William Frank Iv Hulse sold 81,446 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $7.80, for a total value of $635,278.80. Following the completion of the transaction, the chief accounting officer now owns 494,774 shares in the company, valued at $3,859,237.20. The trade was a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the company’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the sale, the insider now owns 310,836 shares in the company, valued at approximately $2,452,496.04. This trade represents a 1.30 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 144,018 shares of company stock worth $1,130,312. Company insiders own 1.30% of the company’s stock.

MiMedx Group Stock Performance

MiMedx Group stock opened at $6.86 on Friday. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of 12.47 and a beta of 1.74. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The firm has a 50 day simple moving average of $7.89 and a 200-day simple moving average of $7.98. MiMedx Group, Inc. has a 1-year low of $5.47 and a 1-year high of $10.14.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The company had revenue of $92.91 million during the quarter, compared to analysts’ expectations of $89.42 million. On average, analysts expect that MiMedx Group, Inc. will post 0.3 EPS for the current year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.